The use of MElatonin in children with Neurodevelopmental Disorders and impaired Sleep: a randomised, double-blind, placebo-controlled, parallel study (MENDS)

RE Appleton,¹* AP Jones,² C Gamble,² PR Williamson,² L Wiggs,³ P Montgomery,⁴ A Sutcliffe,⁵ C Barker¹ and P Gringras⁶

¹Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
²Medicines for Children Research Network Clinical Trials Unit, University of Liverpool, Liverpool, UK
³Department of Psychology, Oxford Brookes University, Oxford, UK
⁴Centre for Evidence Based Intervention, University of Oxford, Oxford, UK
⁵University College London, London, UK
⁶Guy’s and St Thomas’ NHS Foundation Trust, London, UK

*Corresponding author

Executive summary

Health Technology Assessment 2012; Vol. 16: No. 40
DOI: 10.3310/hta16400
Executive summary

Background

Circadian rhythms, including the sleep–wake cycle, are entrained by the transmission of light from the retina to the circadian pacemaker, situated in the suprachiasmatic nucleus (SCN) of the hypothalamus. Light perception is all that is required for synchronisation with the SCN. Melatonin (N-acetyl-5-methoxytryptamine) is a natural substance produced by the pineal gland in the evening in response to SCN signals, with concentrations peaking at approximately midnight and secretion being extremely low during daylight hours. The melatonin signal forms part of the system that can influence sleep-promoting and sleep–wake rhythm-regulating actions. The circadian clock is entrained not only by light but also by behavioural and social cues (zeitgebers). An inability to correctly interpret these zeitgebers in children with neurodevelopmental disorders can lead to abnormalities in circadian rhythm. Children with neurological or developmental disorders or both have a higher prevalence of sleep disturbances, which are frequently chronic and are usually far more difficult to treat than those in their 'normally' developing peers and may result in additional learning and behaviour problems. Disturbed sleep, and specifically discontinuous sleep with frequent awakenings, commonly results in disturbed sleep in their parents and siblings. This may have secondary detrimental effects on families, which may be physical, emotional and social – and, if chronic, may impair their ability to continue in employment or further education. Finally, chronic sleep disturbance in multiply disabled children is a frequent cause of families giving up their care.

Melatonin is unlicensed for use in improving sleep in children, whether or not a child has neurodevelopmental problems, and it is estimated that in the UK there are currently in excess of 6000 children being treated with melatonin. There are at least 50 preparations that are either imported into or manufactured within the UK. Current, and predominantly anecdotal, evidence, together with the rapidly increasing and largely haphazard use of melatonin prescribed by a range of paediatric specialties (community child health, neurology and psychiatry), justified the need to undertake a multicentre, randomised, placebo-controlled, parallel study of melatonin in children with neurodevelopmental delay and a range of neurological disorders and impaired sleep to confirm (or refute) the observation that the drug may increase the total duration of night-time sleep.

Objectives

The primary objective was to determine whether or not immediate-release melatonin is beneficial compared with placebo in improving total sleep time (TST) in children with neurodevelopmental problems, calculated using sleep diaries at 12 weeks compared with baseline. Secondary outcomes included TST calculated using actigraphy data, sleep-onset latency (SOL) (time taken to fall asleep), sleep efficiency, Composite Sleep Disturbance Index score, global measure of child’s sleep quality, Aberrant Behaviour Checklist, Family Impact Module of the Pediatric Quality of Life Inventory (PedsQL™), the Epworth Sleepiness Scale, number and severity of seizures and adverse events. Salivary melatonin concentrations and association of genetic variants with abnormal melatonin production were also investigated. The salivary melatonin analysis was undertaken primarily as an exploratory or hypothesis-generating approach. This was an attempt to enable biochemical phenotyping of those children with a genuinely delayed sleep phase and who might be expected to be better responders to melatonin.
Methods

Population
The population studied was a heterogeneous group comprising a large number of children with a wide range of neurological and developmental disorders, including those with specific genetic disorders but also those without a specific genetic or syndromic diagnosis. This group was chosen because it reflects the typical population who is currently prescribed melatonin in the UK.

Setting
Children were referred by community paediatricians and other clinical colleagues to the principal investigators in the participating sites in hospitals throughout England and Wales. Community paediatricians were informed that the paediatric population who could be referred for consideration of participation in MENDS (MElatonin in children with Neurodevelopmental Disorders and impaired Sleep) must be between the ages of 3 and 15 years and have sleep impairment and neurodevelopmental delay.

Screening
Following referral and at the initial screening visit (T–4W) children were assessed to determine whether or not they were eligible for recruitment into the study.

Inclusion criteria
- Children aged from 3 years to 15 years and 8 months at screening.
- Children with a neurodevelopmental disorder diagnosed by a community paediatrician, paediatric neurologist or paediatric neurodisability consultant.
- Children with an Adaptive Behaviour Assessment System (ABAS) questionnaire score with a percentile rank < 7.
- Children with a reported minimum 5-month history of impaired sleep at screening as defined by:
  - not falling asleep within 1 hour of ‘lights off’ or ‘snuggling down to sleep’ at age-appropriate times for the child in three nights out of five and/or
  - less than 6 hours of continuous sleep in three nights out of five.
- Children whose parents were likely to be able to use the actigraph and complete sleep diaries.
- Children who were able to comply with taking the study drug.
- Families who were English speaking.

Exclusion criteria
- Children treated with melatonin within 5 months of screening.
- Children who had been taking a benzodiazepine (other than as the child's rescue or emergency medication for epilepsy) or other psychoactive drug for < 2 months.
- Children receiving a beta-blocker (minimum of 7 days’ washout required).
- Children receiving a sedative or hypnotic drug, including choral hydrate, triclofos and alimemazine tartrate (Vallergan®, Sanofi-Aventis) (minimum of 14 days’ washout required).
- Children with a known allergy to melatonin.
- Children with a regular consumption of alcohol (more than three times per week).
- Children for whom there are suggestive symptoms of obstructive sleep apnoea syndrome (OSAS) (such as combinations of snoring, gasping, excessive sweating or stopping breathing during sleep), physical signs supportive of OSAS (such as very large tonsils/very small chin) or results of investigations suggesting OSAS (such as overnight pulse oximetry or polysomnography), for which the child should be referred to appropriate respiratory or ear, nose and throat colleagues for specific assessment and treatment.
- Girls or young women who were pregnant at the time of screening (T–4W).
Children who are currently participating in a conflicting clinical study or who have participated in a clinical study involving a medicinal product within the last 3 months.

Following registration, and before randomisation, patients who met the inclusion and exclusion criteria outlined above and who were able to give informed consent entered a 4- to 6-week behaviour therapy period in which a behaviour therapy advice booklet was provided. Sleep was measured using daily sleep diaries and actigraphy. After this period the sleep diaries were reviewed to determine if the sleep problem fulfilled the eligibility criteria. At this time (T0W), possible participants for the interventional stage of the study were reassessed. Patients whose parents/carers had completed sleep diaries for an average of 5 out of 7 nights at baseline (T0W) and whose children still met the inclusion and exclusion criteria were then randomised to receive either melatonin or placebo and were followed for 12 weeks at which point the study terminated (T+12W).

Interventions

At randomisation, children were allocated to receive either active melatonin (Alliance Pharmaceuticals) or matching placebo capsules in doses of 0.5 mg, 2 mg, 6 mg and 12 mg for a period of 12 weeks. The starting dose was 0.5 mg and the dose could be escalated through 2 mg and 6 mg to 12 mg at weekly intervals during the first 4 weeks at the end of which the child was maintained on that dose. The decision to increase the dose was based on a review of set criteria. The dose could also be reduced if the patient's parents/carers felt that the child was experiencing any unwanted side effects from the medication. The capsules could be swallowed whole or opened and the contents mixed with the following vehicles: water, orange juice, semi-skimmed milk, strawberry yoghurt and strawberry jam.

Results

The first patient registered was on 11 December 2007, the first patient randomised was on 28 January 2008, the last patient registered was on 7 May 2010 and the last patient randomised was on 4 June 2010.

A total of 275 children were screened to enter the trial at T–4W; 263 (96%) children were registered and completed the 4- to 6-week behaviour therapy period and 146 (56%) of these children were randomised at T0W, of whom 110 (75%) contributed data for the primary outcome.

The mean difference in TST between the two treatment groups, adjusting for mean baseline total sleep time, was 22.43 minutes [95% confidence interval (CI) 0.52 to 44.34 minutes; p = 0.04] in favour of the melatonin group when using the sleep diaries and slightly less when using actigraphy (13.33 minutes; 95% CI –15.48 to 42.15 minutes). Although the difference between the treatment groups was statistically significant when diaries were used, the 95% CI does not contain the minimum clinically important difference of 60 minutes.

The outcome of SOL measured the time taken for a child to go to sleep from ‘snuggle-down time’. This was calculated using both the actigraphy data and the sleep diary. The mean difference between the treatment groups, adjusting for mean baseline SOL, was –37.49 minutes (95% CI –55.27 to –19.71 minutes; p < 0.0001) in favour of the melatonin group using the sleep diary and –45.34 minutes (95% CI –68.75 to –21.93 minutes; p = 0.0003) using actigraphy. Both measures showed that the time taken to fall asleep by children in the melatonin group was statistically
and clinically significantly less than that in the placebo group. The difference in sleep efficiency between the two treatment groups, adjusted for baseline, was not statistically significant, with an average improvement of 4.03% in the melatonin group (95% CI -0.6 to 8.67%; \( p = 0.0869 \)).

The paucity of salivary melatonin data precludes any meaningful analysis and the genetic analyses are ‘work in progress’.

**Conclusions**

On average, the children treated with melatonin slept for 23 minutes longer than those in the placebo group; however, the upper limit of the CI was < 1 hour, the minimum clinically worthwhile difference specified at the outset of the trial. Melatonin is effective in reducing SOL in children with neurodevelopmental delay, reducing this time by a mean of 45 minutes; a reduction of 30 minutes was specified a priori to be clinically worthwhile.

**Implications for health care**

Sleep disorders are a common presentation in children with a wide variety of neurodevelopmental conditions. Medication should not be the first-line intervention and, in common with previous studies, our behavioural run-in period was successful, with many children no longer meeting eligibility criteria for the study after a relatively short period with a specific evidence-based behaviour therapy advice booklet and monitoring, but no direct work with psychology or other sleep behavioural specialists. However, it is possible that the relatively large ‘dropout’ of patients in the 4- to 6-week behaviour intervention (therapy) phase may also reflect parental perceptions of their child’s sleep problem. The process of formally observing and documenting their child’s sleep pattern in sleep diaries may have unmasked a significant gap between their perceived interpretation of their child’s sleep problem and their child’s actual sleep problem. It would be relatively easy to test this hypothesis in a future randomised controlled trial of behavioural intervention compared with no intervention in this type of population.

Melatonin is more effective than placebo for children with neurodevelopmental delay who have trouble falling asleep. This is a common presenting complaint and melatonin reduces this period by an average of 37 minutes. This is helpful for families desperate to settle their child with neurodevelopmental delay and who may then benefit from a calmer evening either for themselves or for siblings and other family members. However, we found no evidence that this reduction in sleep latency measurably improved the quality of life of families or children’s behaviour over the 3-month period. It did seem to reduce parents’ reports of daytime fatigue, which is an interesting finding that should be further explored.

Although the children fell asleep earlier, they gained very little extra total night-time sleep. An extra 23 minutes of sleep over the whole night is small and was deemed not to be clinically significant for our study. The increase does, of course, vary with individuals and its value is likely to be cumulative. In addition, some families may actually consider that an additional 23 minutes is of benefit.

**Recommendations for research**

- The MENDS study compared melatonin only with placebo. There are a number of other licensed and unlicensed medications for children with sleep problems, including hypnotics and sedatives, and head-to-head trials may help clinicians and families decide which option is likely to be the safest and most helpful.
- Further studies need to be undertaken to try and establish the most appropriate dose and formulation (fast or slow release) of melatonin, incorporating the child’s age, weight and
Executive summary: Use of melatonin in children with neurodevelopmental disorders and impaired sleep

24-hour endogenous melatonin profile, including dim-light melatonin onset and whether they are a fast or slow metaboliser of the drug.

- We were not able to undertake measures of cognition directly. Given that these may reflect important end points around learning potential, they will be important to explore in future intervention trials, however difficult.
- Future studies should be undertaken over a longer period of time and should include both appropriate quality of life and economic evaluations.

**Trial registration**

This trial is registered as ISRCTN05534585.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

**Publication**

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke
Hants RG24 8QW Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series *Health Technology Assessment*.

### Criteria for inclusion in the HTA journal series

Reports are published in the HTA journal series if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the referees and editors.

Reviews in *Health Technology Assessment* are termed ‘systematic’ when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

The research reported in this issue of the journal was commissioned by the HTA programme as project number 05/14/02. The contractual start date was in May 2007. The draft report began editorial review in June 2011 and was accepted for publication in February 2012. As the funder, by devising a commissioning brief, the HTA programme specified the research question and study design. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the referees for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

The views expressed in this publication are those of the authors and not necessarily those of the HTA programme or the Department of Health.

**Editor-in-Chief:** Professor Tom Walley CBE  
**Series Editors:** Dr Martin Ashton-Key, Professor Aileen Clarke, Dr Peter Davidson, Dr Tom Marshall, Professor William McGuire, Professor John Powell, Professor James Raftery, Dr Rob Riemsma, Professor Helen Snooks and Professor Ken Stein  
**Editorial Contact:** edit@southampton.ac.uk

© Queen’s Printer and Controller of HMSO 2012. This work was produced by Appleton et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to NETSCC.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (http://www.publicationethics.org).  

This journal may be freely reproduced for the purposes of private research and study and may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk), on behalf of NETSCC, HTA.  
Printed on acid-free paper in the UK by Charlesworth Press.